Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CYTX

Cytori Therapeutics (CYTX) Stock Price, News & Analysis

Cytori Therapeutics logo

About Cytori Therapeutics Stock (NASDAQ:CYTX)

Key Stats

Today's Range
$1.19
$1.24
50-Day Range
$0.20
$0.21
52-Week Range
$0.20
$0.75
Volume
15,757 shs
Average Volume
915,302 shs
Market Capitalization
$26.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.

Receive CYTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytori Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYTX Stock News Headlines

Cytori Cell Research Institute Inc.
Checkpoint Therapeutics Inc (CKPT)
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…
Sage Therapeutics Inc SAGE
5 Biotech Stocks Under $10 Blasting Higher
8 Stocks Under $10 Ripping Higher
See More Headlines

CYTX Stock Analysis - Frequently Asked Questions

Cytori Therapeutics Inc (NASDAQ:CYTX) posted its quarterly earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.02. The biotechnology company had revenue of $0.70 million for the quarter. Cytori Therapeutics had a negative trailing twelve-month return on equity of 272.70% and a negative net margin of 242.60%.

Cytori Therapeutics shares reverse split before market open on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Inovio Pharmaceuticals (INO), Shire (SHPG), Bank of America (BAC), BCE (BCE), Celldex Therapeutics (CLDX) and Micron Technology (MU).

Company Calendar

Last Earnings
5/14/2019
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CYTX
CUSIP
23283K10
Fax
N/A
Employees
37
Year Founded
N/A

Profitability

Net Income
$-12,630,000.00
Net Margins
-242.60%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.67 million
Book Value
$0.35 per share

Miscellaneous

Free Float
N/A
Market Cap
$26.37 million
Optionable
Not Optionable
Beta
1.96
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:CYTX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners